

**Patient Follow-Up by Visit and Treatment Groups (Year 2 Cohort)**  
(as of December 31, 2011)

Week	Treatment Groups																	
	Ranibizumab Monthly			Ranibizumab Switched			Ranibizumab As Needed			Bevacizumab Monthly			Beverizumab Switched			Beverizumab As Needed		
	Expected	#	Completed %	Expected	#	Completed %	Expected	#	Completed %	Expected	#	Completed %	Expected	#	Completed %	Expected	#	Completed %
All	3,778	3,352	(88.7)	3,539	3,250	(91.8)	7,393	6,778	(91.7)	3,497	3,213	(91.9)	3,364	3,085	(91.7)	6,952	6,347	(91.3)
004	146	145	(99.3)	137	134	(97.8)	287	284	(99.0)	135	134	(99.3)	131	127	(96.9)	269	266	(98.9)
008	146	140	(95.9)	137	131	(95.6)	287	280	(97.6)	135	132	(97.8)	131	125	(95.4)	269	261	(97.0)
012	146	134	(91.8)	137	127	(92.7)	287	269	(93.7)	135	130	(96.3)	131	117	(89.3)	269	251	(93.3)
016	146	136	(93.2)	137	131	(95.6)	287	265	(92.3)	135	123	(91.1)	131	124	(94.7)	269	246	(91.4)
020	146	132	(90.4)	137	127	(92.7)	287	258	(89.9)	135	128	(94.8)	131	126	(96.2)	269	249	(92.6)
024	146	131	(89.7)	138	129	(93.5)	287	267	(93.0)	135	120	(88.9)	131	122	(93.1)	270	249	(92.2)
028	146	128	(87.7)	137	124	(90.5)	287	267	(93.0)	135	124	(91.9)	131	119	(90.8)	269	255	(94.8)
032	146	131	(89.7)	137	126	(92.0)	287	264	(92.0)	135	128	(94.8)	131	120	(91.6)	269	247	(91.8)
036	146	131	(89.7)	137	127	(92.7)	287	264	(92.0)	135	120	(88.9)	131	124	(94.7)	269	243	(90.3)
040	146	138	(94.5)	137	116	(84.7)	287	259	(90.2)	135	128	(94.8)	131	118	(90.1)	269	242	(90.0)
044	146	134	(91.8)	137	127	(92.7)	287	270	(94.1)	135	121	(89.6)	131	118	(90.1)	269	247	(91.8)
048	146	125	(85.6)	137	126	(92.0)	287	263	(91.6)	135	123	(91.1)	131	118	(90.1)	269	243	(90.3)
052	146	141	(96.6)	138	134	(97.1)	287	274	(95.5)	135	129	(95.6)	131	126	(96.2)	270	258	(95.6)
056	146	127	(87.0)	137	128	(93.4)	287	263	(91.6)	135	126	(93.3)	130	115	(88.5)	268	239	(89.2)
060	146	123	(84.2)	137	123	(89.8)	287	260	(90.6)	135	121	(89.6)	130	116	(89.2)	268	244	(91.0)
064	146	129	(88.4)	137	121	(88.3)	286	266	(93.0)	135	119	(88.1)	129	117	(90.7)	267	231	(86.5)
068	146	118	(80.8)	137	131	(95.6)	285	253	(88.8)	134	118	(88.1)	129	120	(93.0)	267	247	(92.5)
072	145	124	(85.5)	136	120	(88.2)	283	249	(88.0)	134	123	(91.8)	127	116	(91.3)	267	242	(90.6)
076	145	124	(85.5)	137	122	(89.1)	282	255	(90.4)	134	121	(90.3)	127	120	(94.5)	268	241	(89.9)
080	145	122	(84.1)	135	123	(91.1)	281	253	(90.0)	134	116	(86.6)	127	114	(89.8)	267	234	(87.6)
084	145	125	(86.2)	134	119	(88.8)	281	247	(87.9)	134	123	(91.8)	127	115	(90.6)	266	235	(88.3)
088	144	124	(86.1)	133	117	(88.0)	280	247	(88.2)	134	116	(86.6)	127	111	(87.4)	265	229	(86.4)
092	144	123	(85.4)	133	117	(88.0)	279	251	(90.0)	134	122	(91.0)	127	111	(87.4)	265	234	(88.3)
096	144	118	(81.9)	133	119	(89.5)	279	241	(86.4)	133	120	(90.2)	127	112	(88.2)	263	233	(88.6)
100	143	115	(80.4)	133	121	(91.0)	278	245	(88.1)	133	119	(89.5)	127	112	(88.2)	262	230	(87.8)
104	141	134	(95.0)	134	130	(97.0)	274	264	(96.4)	133	129	(97.0)	127	122	(96.1)	260	251	(96.5)

**Extended Week 104\* Visual Acuity Summary (Year 2 Cohort)**  
(as of December 31, 2011)

		No.	Visual Acuity Performed Within the Visit Window (%)			
		Week 104				
		VA Exams	104	108	112	116
Total		1,030	(80.1)	(17.7)	(1.7)	(0.6)
Group	1	134	(80.6)	(17.9)	(0.7)	(0.7)
	2	130	(76.9)	(20.0)	(2.3)	(0.8)
	3	264	(80.7)	(17.4)	(1.5)	(0.4)
	4	129	(81.4)	(15.5)	(0.8)	(2.3)
	5	122	(84.4)	(13.9)	(1.6)	(0.0)
	6	251	(78.1)	(19.5)	(2.4)	(0.0)
Drug	1	528	(79.7)	(18.2)	(1.5)	(0.6)
	2	502	(80.5)	(17.1)	(1.8)	(0.6)

\* In order to minimize missing data on the primary outcome measure, the time window for the Week 104 Visit was extended through week 118, the end of the time window for a visit with an ideal date 3 months after 104 weeks. Time windows are ideal data  $\pm$  14 days.